To: Maine Immunization Program Providers
From: Maine Immunization Program
Subject: PREVNAR 13 Guidance
On June 22, 2023, the Advisory Committee on Immunization Practices (ACIP) authorized the use of pneumococcal 20-valent conjugate vaccine in children six weeks through 17 years of age. The PREVNAR 20 builds on PREVNAR 13, including seven additional serotypes (8, 10A, 11A, 12F, 15B, 22F and 33F) shown to be associated with most pneumococcal disease cases in U.S. infants and children.
With PCV20 now available for children, we are aware that providers still have PCV13 in their inventory and would like to offer guidance from the Pfizer manufacturer as what is recommended for remaining doses. Providers should continue to use their remaining inventory of PCV13 vaccine prior to ordering the PCV20.
Once orders for PCV20 have arrived, please be mindful, that the boxes will still have an age recommendation for 18 years and older, however this presentation can also be given to children six weeks through 17 years of age. This packaging will continue to be shipped out until new packaging replaces it.
|
